UNSPSC 51352209: Hexestrol diacetate

This classification denotes a non-steroidal estrogen C22H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0432698UA0, chemically known as phenol,4,4'-((1r,2s)-1,2-diethyl-1,2-ethanediyl)bis-, diacetate, rel-, but more generally known as hexestrol diacetate, which bears US NIH Compound Identifier 656653. European Medicines Agency schedules Hexestrol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02511MIG.

Most nations, for tariff and trade purposes, schedule hexestrol diacetate under HS 29072900 and SITC 51243. As of Q4 2014, HEXESTROL DIACETATE remains US FDA's Preferred Term for this commodity. SMILES: CC[C@H](C1CCC(CC1)OC(=O)C)[C@@H](CC)C2CCC(CC2)OC(=O)C.

UNSPSC 51352209 Hexestrol diacetate is a Commodity code for a specific synthetic estrogen pharmaceutical ingredient; however, recent state and local procurement activity under this code does not appear to isolate or solicit hexestrol diacetate as a standalone product. Instead, state and local governments purchasing under related pharmaceutical codes are acquiring generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing frameworks that bundle hundreds of individual drugs, active ingredients, and formulations into consolidated supplier agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic and OTC pharmaceuticals distributed across participating state and local facilities in Minnesota and Oregon. Participating jurisdictions purchase through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—rather than directly from manufacturers, with suppliers required to support electronic data interchange (EDI) capability, comply with current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) standards, and maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place.

The MMCAP RFP, due March 26, 2026, represents the most visible recent state and local procurement activity linked to this Commodity code and reflects how pharmaceutical procurement operates at the multistate level rather than as isolated active-ingredient buys. Vendors compete primarily on price competitiveness (75 percent of evaluation weight), with secondary criteria including fixed pricing for the contract term (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new responders with optional MMCAP extensions, while incumbent responders' amendments extend through June 30, 2028. Vendors must carry $5 million commercial general liability insurance per occurrence, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Award values are not disclosed, but the cooperative purchasing structure suggests distributed purchasing across multiple state and local health departments, corrections systems, and institutional facilities across participating states.